Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
XTSX:IPA
Price:
6.5 CAD
0.78%
Updated:
May 10, 2024
Immunoprecise Antibodies Ltd
Cost of Revenue
|
Immunoprecise Antibodies Ltd
Cost of Revenue Peer Comparison
Comparables:
ABCL
ARCH
RP
IOT
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Cost of Revenue
-CA$6.4m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Cost of Revenue
-CA$371k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
0%
|
See Also
What is Immunoprecise Antibodies Ltd's Cost of Revenue?
Cost of Revenue
-6.4m
CAD
-6.4m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Cost of Revenue amounts to -6.4m CAD.
What is Immunoprecise Antibodies Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-29%
-29%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Immunoprecise Antibodies Ltd have been -29% over the past three years .
You don't have any saved screeners yet
